Mucosal pathogens causing pneumonia, meningitis, and neonatal sepsis account for more than 2 million deaths each year globally and are associated with substantial disability. We are partnering with more than 25 senior investigators across the UK, The Gambia, Ghana, Kenya, Mali, Malawi, South Africa, Côte d'Ivoire, Nigeria, Senegal and Uganda to improve prevention of life-threatening disease from mucosal pathogens.
- Improved disease intelligence: targeted surveillance of mucosal pathogens incorporating new molecular epidemiology, mathematical modelling, and diagnostic tools to support vaccine evaluation, uptake, and safety monitoring.
- Testing interventions: develop novel trial designs and feasibility studies of vaccines and other interventions as a prelude to large-scale trials.
- New measures of immunity: novel approaches to measuring protective immunity to determine how best to use new and existing vaccines; determine how other non-vaccine interventions, such as harmless commensal bacteria will impact on disease.
- Public engagement: encourage a two-way dialogue with policymakers and the public, ensuring that MPRU research is grounded in the experiences and needs of the people.